Aktieanalys

Egetis Therapeutics: Licensing agreement for Emcitate in Japan - Redeye

Redeye Publicerad: 10 Nov 2023 11:08

Redeye endorses today’s news that Egetis has outlicensed the rights to Emcitate in Japan to Fujimoto. This move, while featuring a modest milestone value of SEK45m, grants Egetis approximately one-third of the future revenue stream. Furthermore, Fujimoto will stand for the regulatory interactions and the remaining development program, which likely will be a relatively small clinical study in Japanese patients. Given that Egetis just recently finalized a strong capital raise, it is reasonable to prioritize royalites in our view. We will return with a more extensive comment soon.

Länk till analysen i sin helhet: https://www.redeye.se/research/958336/egetis-therapeutics-licensing-agreement-for-emcitate-in-japan?utm_source=finwire&utm_medium=RSS

Nyheter om Egetis Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!